# EDGAR Filing Document

**Accession Number:** 0000102816
**File Stem:** 0001752724-25-180813
**Filing Date:** 2025-7
**Character Count:** 38674
**Document Hash:** 2e2cbf6285e949e3578bda7674c49d1d
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001752724-25-180813.hdr.sgml**: 20250728

**ACCESSION NUMBER**: 0001752724-25-180813

**CONFORMED SUBMISSION TYPE**: NPORT-P

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20250531

**FILED AS OF DATE**: 20250728

**DATE AS OF CHANGE**: 20250728

**PERIOD START**: 20250831

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Eaton Vance Growth Trust
- **CENTRAL INDEX KEY:** 0000102816

**ORGANIZATION NAME:**
- **EIN:** 042325690

**FILING VALUES:**
- **FORM TYPE:** NPORT-P
- **SEC ACT:** 1940 Act
- **SEC FILE NUMBER:** 811-01241
- **FILM NUMBER:** 251155335

**BUSINESS ADDRESS:**
- **STREET 1:** ONE POST OFFICE SQUARE
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02109
- **BUSINESS PHONE:** 617-482-8260

**MAIL ADDRESS:**
- **STREET 1:** ONE POST OFFICE SQUARE
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02109

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** EATON VANCE GROWTH TRUST
- **DATE OF NAME CHANGE:** 19930616

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** EATON VANCE GROWTH FUND INC
- **DATE OF NAME CHANGE:** 19920703

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** VANCE SANDERS COMMON STOCK FUND INC
- **DATE OF NAME CHANGE:** 19820915

## Series and Classes Contracts Data

### Eaton Vance Worldwide Health Sciences Fund (Series ID: S000005202)

| Class ID   | Class Name                                         | Ticker Symbol   |
|:---|:---|:---|
| C000014191 | Eaton Vance Worldwide Health Sciences Fund Class A | ETHSX           |
| C000014193 | Eaton Vance Worldwide Health Sciences Fund Class C | ECHSX           |
| C000014194 | Eaton Vance Worldwide Health Sciences Fund Class R | ERHSX           |
| C000081646 | Eaton Vance Worldwide Health Sciences Fund Class I | EIHSX           |

## Nport-Ex

Eaton Vance<br>

Worldwide Health Sciences Fund

May 31, 2025

Portfolio of Investments (Unaudited)

------

Common Stocks — 99.0%

---

| | | |
|:---|:---|:---|
| **Security** | **Shares** | &nbsp;&nbsp;**Value** |
| Biotechnology — 16.7% | Biotechnology — 16.7% | Biotechnology — 16.7% |
| AbbVie, Inc. | 262266 | &nbsp;&nbsp;$48810325 |
| argenx SE ADR<sup>(1)</sup> | 15201 | &nbsp;&nbsp;&nbsp;&nbsp; 8714125 |
| Centessa Pharmaceuticals PLC ADR<sup>(1)</sup> | 146529 | &nbsp;&nbsp;&nbsp;&nbsp; 1979607 |
| CSL Ltd. | 115187 | &nbsp;&nbsp;&nbsp;&nbsp; 18380391 |
| Gilead Sciences, Inc. | 225867 | &nbsp;&nbsp;&nbsp;&nbsp; 24863440 |
| Neurocrine Biosciences, Inc.<sup>(1)</sup> | 122298 | &nbsp;&nbsp;&nbsp;&nbsp; 15045100 |
| NewAmsterdam Pharma Co. NV<sup>(1)</sup> | 115421 | &nbsp;&nbsp;&nbsp;&nbsp; 2090274 |
| Vertex Pharmaceuticals, Inc.<sup>(1)</sup> | 53839 | &nbsp;&nbsp;&nbsp;&nbsp; 23799530 |
|  |  | &nbsp;&nbsp;**$143682792** |
| Health Care Distributors — 3.4% | Health Care Distributors — 3.4% | Health Care Distributors — 3.4% |
| Amplifon SpA | 403407 | &nbsp;&nbsp;$9273012 |
| McKesson Corp. | 27447 | &nbsp;&nbsp;&nbsp;&nbsp; 19748391 |
|  |  | &nbsp;&nbsp;**$29021403** |
| Health Care Equipment — 21.1% | Health Care Equipment — 21.1% | Health Care Equipment — 21.1% |
| Abbott Laboratories | 321656 | &nbsp;&nbsp;$42966809 |
| Boston Scientific Corp.<sup>(1)</sup> | 243280 | &nbsp;&nbsp;&nbsp;&nbsp; 25607653 |
| Edwards Lifesciences Corp.<sup>(1)</sup> | 200470 | &nbsp;&nbsp;&nbsp;&nbsp; 15680763 |
| IDEXX Laboratories, Inc.<sup>(1)</sup> | 32781 | &nbsp;&nbsp;&nbsp;&nbsp; 16828454 |
| Intuitive Surgical, Inc.<sup>(1)</sup> | 55020 | &nbsp;&nbsp;&nbsp;&nbsp; 30389747 |
| Medtronic PLC | 157694 | &nbsp;&nbsp;&nbsp;&nbsp; 13085448 |
| Straumann Holding AG | 95686 | &nbsp;&nbsp;&nbsp;&nbsp; 12307911 |
| Stryker Corp. | 64081 | &nbsp;&nbsp;&nbsp;&nbsp; 24519954 |
|  |  | &nbsp;&nbsp;**$181386739** |
| Health Care Services — 0.7% | Health Care Services — 0.7% | Health Care Services — 0.7% |
| Option Care Health, Inc.<sup>(1)</sup> | 178995 | &nbsp;&nbsp;$5849557 |
|  |  | &nbsp;&nbsp;**$5849557** |
| Health Care Supplies — 4.8% | Health Care Supplies — 4.8% | Health Care Supplies — 4.8% |
| Alcon AG | 143929 | &nbsp;&nbsp;$12394718 |
| Align Technology, Inc.<sup>(1)</sup> | 46541 | &nbsp;&nbsp;&nbsp;&nbsp; 8421129 |
| Asahi Intecc Co. Ltd. | 255800 | &nbsp;&nbsp;&nbsp;&nbsp; 3966644 |
| Coloplast AS, Class B | 81388 | &nbsp;&nbsp;&nbsp;&nbsp; 7912589 |
| Cooper Cos., Inc.<sup>(1)</sup> | 128221 | &nbsp;&nbsp;&nbsp;&nbsp; 8754930 |
|  |  | &nbsp;&nbsp;**$41450010** |
| Health Care Technology — 0.2% | Health Care Technology — 0.2% | Health Care Technology — 0.2% |
| JMDC, Inc. | 83700 | &nbsp;&nbsp;$1890185 |
|  |  | &nbsp;&nbsp;**$1890185** |

---

---

| | | |
|:---|:---|:---|
| **Security** | **Shares** | &nbsp;&nbsp;**Value** |
| Life Sciences Tools & Services — 7.1% | Life Sciences Tools & Services — 7.1% | Life Sciences Tools & Services — 7.1% |
| Danaher Corp. | 100636 | &nbsp;&nbsp;$19110776 |
| Lonza Group AG | 25269 | &nbsp;&nbsp;&nbsp;&nbsp; 17534293 |
| Mettler-Toledo International, Inc.<sup>(1)</sup> | &nbsp;&nbsp;&nbsp;&nbsp;8731 | &nbsp;&nbsp;&nbsp;&nbsp; 10088845 |
| Thermo Fisher Scientific, Inc. | 36137 | &nbsp;&nbsp;&nbsp;&nbsp; 14556706 |
|  |  | &nbsp;&nbsp;**$61290620** |
| Managed Health Care — 5.1% | Managed Health Care — 5.1% | Managed Health Care — 5.1% |
| Centene Corp.<sup>(1)</sup> | 164203 | &nbsp;&nbsp;$9267617 |
| Elevance Health, Inc. | 34372 | &nbsp;&nbsp;&nbsp;&nbsp; 13193349 |
| UnitedHealth Group, Inc. | 70766 | &nbsp;&nbsp;&nbsp;&nbsp; 21364963 |
|  |  | &nbsp;&nbsp;**$43825929** |
| Metal, Glass & Plastic Containers — 0.8% | Metal, Glass & Plastic Containers — 0.8% | Metal, Glass & Plastic Containers — 0.8% |
| AptarGroup, Inc. | 44675 | &nbsp;&nbsp;$7076520 |
|  |  | &nbsp;&nbsp;**$7076520** |
| Pharmaceuticals — 39.1% | Pharmaceuticals — 39.1% | Pharmaceuticals — 39.1% |
| AstraZeneca PLC | 318544 | &nbsp;&nbsp;$46661584 |
| Bristol-Myers Squibb Co. | 497733 | &nbsp;&nbsp;&nbsp;&nbsp; 24030549 |
| Eli Lilly & Co. | 115906 | &nbsp;&nbsp;&nbsp;&nbsp; 85500379 |
| Johnson & Johnson | 195782 | &nbsp;&nbsp;&nbsp;&nbsp; 30387324 |
| Merck & Co., Inc. | 126571 | &nbsp;&nbsp;&nbsp;&nbsp; 9725716 |
| Novo Nordisk AS, Class B | 565583 | &nbsp;&nbsp;&nbsp;&nbsp; 40183430 |
| Roche Holding AG PC | 127381 | &nbsp;&nbsp;&nbsp;&nbsp; 41264705 |
| Royalty Pharma PLC, Class A | 180612 | &nbsp;&nbsp;&nbsp;&nbsp; 5938523 |
| Sanofi SA | 224029 | &nbsp;&nbsp;&nbsp;&nbsp; 22188032 |
| Zoetis, Inc. | 184111 | &nbsp;&nbsp;&nbsp;&nbsp; 31046638 |
|  |  | &nbsp;&nbsp;**$336926880** |
| Total Common Stocks<br> (identified cost $536,831,289) |  | &nbsp;&nbsp;**$852400635** |

---

Convertible Bonds — 0.0%<sup>†</sup>

---

| | | |
|:---|:---|:---|
| **Security** | **Principal<br> Amount<br> (000s omitted)** | &nbsp;&nbsp;**Value** |
| Biotechnology — 0.0%<sup>†</sup> | Biotechnology — 0.0%<sup>†</sup> | Biotechnology — 0.0%<sup>†</sup> |
| Caris Life Sciences, Inc., 8.00%, 1/1/26<sup>(2)</sup> | $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;235 | &nbsp;&nbsp;$235294 |
| Total Convertible Bonds<br> (identified cost $235,294) |  | &nbsp;&nbsp;**$235294** |

---

------

Eaton Vance<br>

Worldwide Health Sciences Fund

May 31, 2025

Portfolio of Investments (Unaudited) — continued

------

Convertible Preferred Stocks — 0.6%

---

| | | |
|:---|:---|:---|
| **Security** | **Shares** | &nbsp;&nbsp;**Value** |
| Biotechnology — 0.6% | Biotechnology — 0.6% | Biotechnology — 0.6% |
| Caris Life Sciences, Inc.: |  |  |
| &nbsp;&nbsp;&nbsp;Series D<sup>(1)(2)(3)</sup> | 370370 | &nbsp;&nbsp;$2999997 |
| &nbsp;&nbsp;&nbsp;Series E<sup>(1)(2)(3)</sup> | 94408 | &nbsp;&nbsp;&nbsp;&nbsp; 764705 |
| &nbsp;&nbsp;&nbsp;Series F<sup>(1)(2)(3)</sup> | 123456 | &nbsp;&nbsp;&nbsp;&nbsp; 999993 |
| Total Convertible Preferred Stocks<br> (identified cost $4,764,698) |  | &nbsp;&nbsp;**$4764695** |

---

Short-Term Investments — 0.0%<sup>†</sup>

---

| | | |
|:---|:---|:---|
| **Security** | **Shares** | &nbsp;&nbsp;**Value** |
| Morgan Stanley Institutional Liquidity Funds - Government Portfolio, Institutional Class, 4.22%<sup>(4)</sup> | &nbsp;&nbsp;&nbsp;&nbsp;9518 | &nbsp;&nbsp;$9518 |
| Total Short-Term Investments<br> (identified cost $9,518) |  | &nbsp;&nbsp;**$9518** |
| Total Investments — 99.6%<br> (identified cost $541,840,799) |  | &nbsp;&nbsp;**$857410142** |
| Other Assets, Less Liabilities — 0.4% |  | &nbsp;&nbsp;**$3435788** |
| Net Assets — 100.0% |  | &nbsp;&nbsp;**$860845930** |

---

---

| | |
|:---|:---|
| The percentage shown for each investment category in the Portfolio of Investments is based on net assets. | The percentage shown for each investment category in the Portfolio of Investments is based on net assets. |
| <sup>†</sup> | Amount is less than 0.05% or (0.05)%, as applicable. |
| <sup>(1)</sup> | Non-income producing security. |

---

<sup>(2)</sup> Security is valued using significant unobservable inputs and is categorized as Level 3 in the fair value hierarchy.

<sup>(3)</sup> Restricted security.

<sup>(4)</sup> May be deemed to be an affiliated investment company. The rate shown is the annualized seven-day yield as of May 31, 2025.

---

| | | |
|:---|:---|:---|
| Country Concentration of Portfolio | Country Concentration of Portfolio | Country Concentration of Portfolio |
| **Country** | &nbsp;&nbsp;&nbsp;**Percentage<br> of Net Assets** | &nbsp;&nbsp;&nbsp;**Value** |
| United States | &nbsp;&nbsp;&nbsp;82.1% | &nbsp;&nbsp;&nbsp;$706876095 |
| Denmark | &nbsp;&nbsp;&nbsp;&nbsp;5.6 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;48096019 |
| United Kingdom | &nbsp;&nbsp;&nbsp;&nbsp;5.4 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;46661584 |
| Switzerland | &nbsp;&nbsp;&nbsp;&nbsp;3.5 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;29842204 |
| Netherlands | &nbsp;&nbsp;&nbsp;&nbsp;1.2 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10804399 |
| Italy | &nbsp;&nbsp;&nbsp;&nbsp;1.1 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9273012 |
| Japan | &nbsp;&nbsp;&nbsp;&nbsp;0.7 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5856829 |
| **Total Investments** | &nbsp;&nbsp;&nbsp;**99.6%** | &nbsp;&nbsp;&nbsp;**$857410142** |

---

---

| | |
|:---|:---|
| **Abbreviations:** | **Abbreviations:** |
| ADR | – American Depositary Receipt |
| PC | – Participation Certificate |

---

The Fund did not have any open derivative instruments at May 31, 2025.

------

Eaton Vance<br>

Worldwide Health Sciences Fund

May 31, 2025

Portfolio of Investments (Unaudited) — continued

------

Restricted Securities

At May 31, 2025, the Fund owned the following security (representing 0.6% of net assets) which was restricted as to public resale and not registered under the Securities Act of 1933 (excluding Rule 144A securities). The Fund has limited registration rights with respect to this security. The value of restricted securities is determined based on valuations provided by brokers when available, or if not available, they are valued by the investment adviser as the Trustees' valuation designee.

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Description** | &nbsp;&nbsp;&nbsp;&nbsp;**Date(s) of<br> Acquisition** | &nbsp;&nbsp;&nbsp;&nbsp;**Shares** | &nbsp;&nbsp;&nbsp;&nbsp;**Cost** | &nbsp;&nbsp;&nbsp;&nbsp;**Value** |
| **Convertible Preferred Stocks** |  |  |  |  |
| Caris Life Sciences, Inc., Series D | &nbsp;&nbsp;&nbsp;&nbsp;5/12/21, 9/23/21 | &nbsp;&nbsp;&nbsp;&nbsp;370370 | &nbsp;&nbsp;&nbsp;&nbsp;$3000000 | &nbsp;&nbsp;&nbsp;&nbsp;$2999997 |
| Caris Life Sciences, Inc., Series E | &nbsp;&nbsp;&nbsp;&nbsp;4/1/25 | &nbsp;&nbsp;&nbsp;&nbsp; 94408 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 764705 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 764705 |
| Caris Life Sciences, Inc., Series F | &nbsp;&nbsp;&nbsp;&nbsp;4/1/25 | &nbsp;&nbsp;&nbsp;&nbsp;123456 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 999993 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 999993 |
| **Total Restricted Securities** |  |  | &nbsp;&nbsp;&nbsp;&nbsp;**$4764698** | &nbsp;&nbsp;&nbsp;&nbsp;**$4764695** |

---

Affiliated Investments

At May 31, 2025, the value of the Fund's investment in funds that may be deemed to be affiliated was $9,518, which represents less than 0.05% of the Fund's net assets. Transactions in such investments by the Fund for the fiscal year to date ended May 31, 2025 were as follows:

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **Name** | **Value,<br> beginning<br> of period** | **Purchases** | **Sales<br> proceeds** | **Net realized<br> gain (loss)** | **Change in<br> unrealized<br> appreciation<br> (depreciation)** | **Value, end<br> of period** | **Dividend<br> income** | **Shares,<br> end of period** |
| **Short-Term Investments** | **Short-Term Investments** | **Short-Term Investments** | **Short-Term Investments** | **Short-Term Investments** | **Short-Term Investments** | **Short-Term Investments** | **Short-Term Investments** | **Short-Term Investments** |
| Liquidity Fund, Institutional Class<sup>(1)</sup> | $1285435 | $83157259 | $(84433176) | $— | $— | $9518 | $56838 | 9518 |

---

<sup>(1)</sup> Represents investment in Morgan Stanley Institutional Liquidity Funds - Government Portfolio.

Fair Value Measurements

Under generally accepted accounting principles for fair value measurements, a three-tier hierarchy to prioritize the assumptions, referred to as inputs, is used in valuation techniques to measure fair value. The three-tier hierarchy of inputs is summarized in the three broad levels listed below.

• Level 1 – quoted prices in active markets for identical investments

• Level 2 – other significant observable inputs (including quoted prices for similar investments, interest rates, prepayment speeds, credit risk, etc.)

• Level 3 – significant unobservable inputs (including a fund's own assumptions in determining the fair value of investments)

In cases where the inputs used to measure fair value fall in different levels of the fair value hierarchy, the level disclosed is determined based on the lowest level input that is significant to the fair value measurement in its entirety. The inputs or methodology used for valuing securities are not necessarily an indication of the risk associated with investing in those securities.

At May 31, 2025, the hierarchy of inputs used in valuing the Fund's investments, which are carried at fair value, were as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Asset Description** | &nbsp;&nbsp;**Level 1** | &nbsp;&nbsp;&nbsp;&nbsp;**Level 2** | &nbsp;&nbsp;&nbsp;&nbsp;**Level 3\*** | &nbsp;&nbsp;&nbsp;&nbsp;**Total** |
| Common Stocks: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Biotechnology | &nbsp;&nbsp;$125302401 | &nbsp;&nbsp;&nbsp;&nbsp;$18380391 | &nbsp;&nbsp;&nbsp;&nbsp;$— | &nbsp;&nbsp;&nbsp;&nbsp;$143682792 |
| &nbsp;&nbsp;&nbsp;Health Care Distributors | &nbsp;&nbsp;&nbsp;&nbsp; 19748391 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 9273012 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; — | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 29021403 |
| &nbsp;&nbsp;&nbsp;Health Care Equipment | &nbsp;&nbsp;&nbsp;&nbsp;169078828 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 12307911 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; — | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;181386739 |
| &nbsp;&nbsp;&nbsp;Health Care Services | &nbsp;&nbsp;&nbsp;&nbsp; 5849557 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; — | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; — | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 5849557 |
| &nbsp;&nbsp;&nbsp;Health Care Supplies | &nbsp;&nbsp;&nbsp;&nbsp; 17176059 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 24273951 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; — | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 41450010 |

---

------

Eaton Vance<br>

Worldwide Health Sciences Fund

May 31, 2025

Portfolio of Investments (Unaudited) — continued

------

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Asset Description (continued)** | &nbsp;&nbsp;**Level 1** | &nbsp;&nbsp;&nbsp;&nbsp;**Level 2** | &nbsp;&nbsp;&nbsp;&nbsp;**Level 3\*** | &nbsp;&nbsp;&nbsp;&nbsp;**Total** |
| &nbsp;&nbsp;&nbsp;Health Care Technology | &nbsp;&nbsp;$— | &nbsp;&nbsp;&nbsp;&nbsp;$1890185 | &nbsp;&nbsp;&nbsp;&nbsp;$— | &nbsp;&nbsp;&nbsp;&nbsp;$1890185 |
| &nbsp;&nbsp;&nbsp;Life Sciences Tools & Services | &nbsp;&nbsp;&nbsp;&nbsp; 43756327 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 17534293 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; — | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 61290620 |
| &nbsp;&nbsp;&nbsp;Managed Health Care | &nbsp;&nbsp;&nbsp;&nbsp; 43825929 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; — | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; — | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 43825929 |
| &nbsp;&nbsp;&nbsp;Metal, Glass & Plastic Containers | &nbsp;&nbsp;&nbsp;&nbsp; 7076520 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; — | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; — | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 7076520 |
| &nbsp;&nbsp;&nbsp;Pharmaceuticals | &nbsp;&nbsp;&nbsp;&nbsp;186629129 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;150297751 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; — | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;336926880 |
| **Total Common Stocks** | &nbsp;&nbsp;**$618443141** | &nbsp;&nbsp;&nbsp;&nbsp;**$233,957,494\*\*** | &nbsp;&nbsp;&nbsp;&nbsp;**$—** | &nbsp;&nbsp;&nbsp;&nbsp;**$852400635** |
| Convertible Bonds | &nbsp;&nbsp;$— | &nbsp;&nbsp;&nbsp;&nbsp;$— | &nbsp;&nbsp;&nbsp;&nbsp;$235294 | &nbsp;&nbsp;&nbsp;&nbsp;$235294 |
| Convertible Preferred Stocks | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; — | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; — | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4764695 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 4764695 |
| Short-Term Investments | &nbsp;&nbsp;&nbsp;&nbsp; 9518 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; — | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; — | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 9518 |
| **Total Investments** | &nbsp;&nbsp;**$618452659** | &nbsp;&nbsp;&nbsp;&nbsp;**$233957494** | &nbsp;&nbsp;&nbsp;&nbsp;**$4999989** | &nbsp;&nbsp;&nbsp;&nbsp;**$857410142** |

---

\* None of the unobservable inputs for Level 3 assets, individually or collectively, had a material impact on the Fund.

\*\* Includes foreign equity securities whose values were adjusted to reflect market trading of comparable securities or other correlated instruments that occurred after the close of trading in their applicable foreign markets.

Level 3 investments at the beginning and/or end of the period in relation to net assets were not significant and accordingly, a reconciliation of Level 3 assets for the fiscal year to date ended May 31, 2025 is not presented.

For information on the Fund's policy regarding the valuation of investments and other significant accounting policies, please refer to the Fund's most recent annual or semi-annual financial statements.

## Form NPORT-P: Monthly Portfolio Investments Report

### NPORT-P: Part A: General Information

**Item A.1. Information about the Registrant.**

- **a. Name of Registrant:** Eaton Vance Growth Trust

- **b. Investment Company Act file number:** 811-01241

- **c. CIK number of Registrant:** 0000102816

- **d. LEI of Registrant:** 549300IUJG72RXOVY252

- **e. Address and telephone number of Registrant.**

  - **Street Address 1:** One Post Office Square

  - **City:** Boston

  - **State:** MA

  - **Foreign country:** US

  - **Zip / Postal Code:** 02109

  - **Telephone number:** 617-482-8260

**Item A.2. Information about the Series.**

- **a. Name of Series:** Eaton Vance Worldwide Health Sciences Fund

- **b. EDGAR series identifier (if any):** S000005202

- **c. LEI of Series:** 549300CI26YJYCASE766

**Item A.3. Reporting period.**

- **a. Date of fiscal year-end:** 2025-08-31

- **b. Date as of which information is reported:** 2025-05-31

**Item A.4. Final filing**

Does the Fund anticipate that this will be its final filing on Form N-PORT? **No**

### Fund Information

**Total Assets:** $864120351.56

**Total Liabilities:** $2436818.62

**Net Assets:** $861683532.94

**Monthly Return Information**

| Class               | Month 1 Return (%)   | Month 2 Return (%)   | Month 3 Return (%)   |
|:---|:---|:---|:---|
| Class ID C000081646 | -4.01%               | -1.73%               | -3.59%               |
| Class ID C000014193 | -4.15%               | -1.79%               | -3.65%               |
| Class ID C000014191 | -4.01%               | -1.79%               | -3.57%               |
| Class ID C000014194 | -4.06%               | -1.78%               | -3.62%               |

**Monthly Gains & Losses**

| Period   | Net Realized Gain/Loss   | Net Unrealized Appreciation/Depreciation   |
|:---|:---|:---|
| Month 1  | $110906.64               | $-41309335.25                              |
| Month 2  | $2858300.13              | $-19957973.86                              |
| Month 3  | $6015196.26              | $-39525311.42                              |

### Schedule of Portfolio Investments

| Name                             | Title                                                               | Identifiers                                   | Payoff Profile   | Asset Category   | Issuer Category   | Country   |   Balance | Units   | Value (USD)   | % of Net Assets   | Maturity Date   | Coupon Type   | Annualized Rate (%)   | Restricted?   |   Fair Value Level | Lending Status   |
|:---|:---|:---|:---|:---|:---|:---|---:|:---|:---|:---|:---|:---|:---|:---|---:|:---|
| Amplifon SpA                     | Amplifon SpA                                                        | CUSIP: 000000000<br>LEI: ZYXJDNVM2JI3VBM8G556 | Long             | EC               | CORP              | IT        |    403407 | NS      | $9273011.91   | 1.08%             |  |  |  | No            |                  2 | On Loan: No      |
| Newamsterdam Pharma Co NV        | Newamsterdam Pharma Co NV                                           | CUSIP: 000000000<br>LEI: 984500B6549TF6E14D36 | Long             | EC               | CORP              | NL        |    115421 | NS      | $2090274.31   | 0.24%             |  |  |  | No            |                  1 | On Loan: No      |
| Vertex Pharmaceuticals Inc       | Vertex Pharmaceuticals Inc                                          | CUSIP: 92532F100<br>LEI: 54930015RAQRRZ5ZGJ91 | Long             | EC               | CORP              | US        |     53839 | NS      | $23799529.95  | 2.76%             |  |  |  | No            |                  1 | On Loan: No      |
| Johnson & Johnson                | Johnson & Johnson                                                   | CUSIP: 478160104<br>LEI: 549300G0CFPGEF6X2043 | Long             | EC               | CORP              | US        |    195782 | NS      | $30387324.22  | 3.53%             |  |  |  | No            |                  1 | On Loan: No      |
| UnitedHealth Group Inc           | UnitedHealth Group Inc                                              | CUSIP: 91324P102<br>LEI: 549300GHBMY8T5GXDE41 | Long             | EC               | CORP              | US        |     70766 | NS      | $21364963.06  | 2.48%             |  |  |  | No            |                  1 | On Loan: No      |
| Straumann Holding AG             | Straumann Holding AG                                                | CUSIP: 000000000<br>LEI: 50670046ML5FVIM60Z37 | Long             | EC               | CORP              | CH        |     95686 | NS      | $12307911.13  | 1.43%             |  |  |  | No            |                  2 | On Loan: No      |
| AbbVie Inc                       | AbbVie Inc                                                          | CUSIP: 00287Y109<br>LEI: FR5LCKFTG8054YNNRU85 | Long             | EC               | CORP              | US        |    262266 | NS      | $48810325.26  | 5.66%             |  |  |  | No            |                  1 | On Loan: No      |
| Thermo Fisher Scientific Inc     | Thermo Fisher Scientific Inc                                        | CUSIP: 883556102<br>LEI: HCHV7422L5HDJZCRFL38 | Long             | EC               | CORP              | US        |     36137 | NS      | $14556706.34  | 1.69%             |  |  |  | No            |                  1 | On Loan: No      |
| Cooper Cos Inc/The               | Cooper Cos Inc/The                                                  | CUSIP: 216648501<br>LEI: QJKMVPIGLH7530PCUE20 | Long             | EC               | CORP              | US        |    128221 | NS      | $8754929.88   | 1.02%             |  |  |  | No            |                  1 | On Loan: No      |
| Medtronic PLC                    | Medtronic PLC                                                       | CUSIP: 000000000<br>LEI: 549300GX3ZBSQWUXY261 | Long             | EC               | CORP              | IE        |    157694 | NS      | $13085448.12  | 1.52%             |  |  |  | No            |                  1 | On Loan: No      |
| Centene Corp                     | Centene Corp                                                        | CUSIP: 15135B101<br>LEI: 549300Z7JJ4TQSQGT333 | Long             | EC               | CORP              | US        |    164203 | NS      | $9267617.32   | 1.08%             |  |  |  | No            |                  1 | On Loan: No      |
| Roche Holding AG                 | Roche Holding AG                                                    | CUSIP: 000000000<br>LEI: 549300U41AUUVOAAOB37 | Long             | EC               | CORP              | CH        |    127381 | NS      | $41264705.35  | 4.79%             |  |  |  | No            |                  2 | On Loan: No      |
| Zoetis Inc                       | Zoetis Inc                                                          | CUSIP: 98978V103<br>LEI: 549300HD9Q1LOC9KLJ48 | Long             | EC               | CORP              | US        |    184111 | NS      | $31046637.93  | 3.60%             |  |  |  | No            |                  1 | On Loan: No      |
| Boston Scientific Corp           | Boston Scientific Corp                                              | CUSIP: 101137107<br>LEI: Y6ZDD9FP4P8JSSJMW954 | Long             | EC               | CORP              | US        |    243280 | NS      | $25607652.80  | 2.97%             |  |  |  | No            |                  1 | On Loan: No      |
| Elevance Health Inc              | Elevance Health Inc                                                 | CUSIP: 036752103<br>LEI: 8MYN82XMYQH89CTMTH67 | Long             | EC               | CORP              | US        |     34372 | NS      | $13193348.48  | 1.53%             |  |  |  | No            |                  1 | On Loan: No      |
| Novo Nordisk A/S                 | Novo Nordisk A/S                                                    | CUSIP: 000000000<br>LEI: 549300DAQ1CVT6CXN342 | Long             | EC               | CORP              | DK        |    565583 | NS      | $40183430.28  | 4.66%             |  |  |  | No            |                  2 | On Loan: No      |
| Align Technology Inc             | Align Technology Inc                                                | CUSIP: 016255101<br>LEI: 549300N5YSE0U3LCP840 | Long             | EC               | CORP              | US        |     46541 | NS      | $8421128.54   | 0.98%             |  |  |  | No            |                  1 | On Loan: No      |
| Stryker Corp                     | Stryker Corp                                                        | CUSIP: 863667101<br>LEI: 5493002F0SC4JTBU5137 | Long             | EC               | CORP              | US        |     64081 | NS      | $24519953.84  | 2.85%             |  |  |  | No            |                  1 | On Loan: No      |
| CARIS LIFE SCIENCES, INC         | CARIS LIFE SCIENCES, INC                                            | CUSIP: 000000000<br>LEI: N/A                  | Long             | EP               | CORP              | US        |     94408 | NS      | $764704.80    | 0.09%             |  |  |  | No            |                  3 | On Loan: No      |
| JMDC Inc                         | JMDC Inc                                                            | CUSIP: 000000000<br>LEI: 3538002M2SQV6WJ6MQ67 | Long             | EC               | CORP              | JP        |     83700 | NS      | $1890184.77   | 0.22%             |  |  |  | No            |                  2 | On Loan: No      |
| Centessa Pharmaceuticals PLC     | Centessa Pharmaceuticals PLC                                        | CUSIP: 152309100<br>LEI: 213800GIDAARDSKOI827 | Long             | EC               | CORP              | GB        |    146529 | NS      | $1979606.79   | 0.23%             |  |  |  | No            |                  1 | On Loan: No      |
| AstraZeneca PLC                  | AstraZeneca PLC                                                     | CUSIP: 000000000<br>LEI: PY6ZZQWO2IZFZC3IOL08 | Long             | EC               | CORP              | GB        |    318544 | NS      | $46661583.92  | 5.42%             |  |  |  | No            |                  2 | On Loan: No      |
| Intuitive Surgical Inc           | Intuitive Surgical Inc                                              | CUSIP: 46120E602<br>LEI: 54930052SRG011710797 | Long             | EC               | CORP              | US        |     55020 | NS      | $30389746.80  | 3.53%             |  |  |  | No            |                  1 | On Loan: No      |
| Alcon AG                         | Alcon AG                                                            | CUSIP: 000000000<br>LEI: 549300LDT5AP8S0NBM78 | Long             | EC               | CORP              | CH        |    143929 | NS      | $12394718.48  | 1.44%             |  |  |  | No            |                  2 | On Loan: No      |
| AptarGroup Inc                   | AptarGroup Inc                                                      | CUSIP: 038336103<br>LEI: VNPEQDQFAA7IY1T2PX43 | Long             | EC               | CORP              | US        |     44675 | NS      | $7076520.00   | 0.82%             |  |  |  | No            |                  1 | On Loan: No      |
| Abbott Laboratories              | Abbott Laboratories                                                 | CUSIP: 002824100<br>LEI: HQD377W2YR662HK5JX27 | Long             | EC               | CORP              | US        |    321656 | NS      | $42966808.48  | 4.99%             |  |  |  | No            |                  1 | On Loan: No      |
| CARIS LIFE SCIENCES, INC         | CARIS LIFE SCIENCES, INC                                            | CUSIP: 000000000<br>LEI: N/A                  | Long             | EP               | CORP              | US        |    123456 | NS      | $999993.60    | 0.12%             |  |  |  | No            |                  3 | On Loan: No      |
| Lonza Group AG                   | Lonza Group AG                                                      | CUSIP: 000000000<br>LEI: 549300EFW4H2TCZ71055 | Long             | EC               | CORP              | CH        |     25269 | NS      | $17534292.72  | 2.03%             |  |  |  | No            |                  2 | On Loan: No      |
| Asahi Intecc Co Ltd              | Asahi Intecc Co Ltd                                                 | CUSIP: 000000000<br>LEI: 353800J3AV2SCNIO8L39 | Long             | EC               | CORP              | JP        |    255800 | NS      | $3966644.25   | 0.46%             |  |  |  | No            |                  2 | On Loan: No      |
| CSL Ltd                          | CSL Ltd                                                             | CUSIP: 000000000<br>LEI: 529900ECSECK5ZDQTE14 | Long             | EC               | CORP              | AU        |    115187 | NS      | $18380390.96  | 2.13%             |  |  |  | No            |                  2 | On Loan: No      |
| Edwards Lifesciences Corp        | Edwards Lifesciences Corp                                           | CUSIP: 28176E108<br>LEI: YA13X31F3V31L8TMPR58 | Long             | EC               | CORP              | US        |    200470 | NS      | $15680763.40  | 1.82%             |  |  |  | No            |                  1 | On Loan: No      |
| Argenx SE                        | Argenx SE                                                           | CUSIP: 04016X101<br>LEI: 7245009C5FZE6G9ODQ71 | Long             | EC               | CORP              | NL        |     15201 | NS      | $8714125.26   | 1.01%             |  |  |  | No            |                  1 | On Loan: No      |
| Morgan Stanley & Co. LLC         | Morgan Stanley Institutional Liquidity Funds - Government Portfolio | CUSIP: 61747C707<br>LEI: 549300BI6Y5SI6BYPB26 | Long             | STIV             | RF                | US        |      9518 | NS      | $9517.61      | 0.00%             |  |  |  | No            |                  1 | On Loan: No      |
| Option Care Health Inc           | Option Care Health Inc                                              | CUSIP: 68404L201<br>LEI: 549300DI3Q5ACSYJRI17 | Long             | EC               | CORP              | US        |    178995 | NS      | $5849556.60   | 0.68%             |  |  |  | No            |                  1 | On Loan: No      |
| Sanofi SA                        | Sanofi SA                                                           | CUSIP: 000000000<br>LEI: 549300E9PC51EN656011 | Long             | EC               | CORP              | FR        |    224029 | NS      | $22188032.28  | 2.57%             |  |  |  | No            |                  2 | On Loan: No      |
| Neurocrine Biosciences Inc       | Neurocrine Biosciences Inc                                          | CUSIP: 64125C109<br>LEI: 549300FECER0XBN49756 | Long             | EC               | CORP              | US        |    122298 | NS      | $15045099.96  | 1.75%             |  |  |  | No            |                  1 | On Loan: No      |
| McKesson Corp                    | McKesson Corp                                                       | CUSIP: 58155Q103<br>LEI: 549300WZWOM80UCFSF54 | Long             | EC               | CORP              | US        |     27447 | NS      | $19748390.97  | 2.29%             |  |  |  | No            |                  1 | On Loan: No      |
| Humana Inc                       | Humana Inc                                                          | CUSIP: 444859102<br>LEI: 529900YLDW34GJAO4J06 | Long             | EC               | CORP              | US        |     14558 | NS      | $3393906.54   | 0.39%             |  |  |  | No            |                  1 | On Loan: No      |
| Danaher Corp                     | Danaher Corp                                                        | CUSIP: 235851102<br>LEI: S4BKK9OTCEWQ3YHPFM11 | Long             | EC               | CORP              | US        |    100636 | NS      | $19110776.40  | 2.22%             |  |  |  | No            |                  1 | On Loan: No      |
| CARIS LIFE SCIENCES, INC         | CARIS LIFE SCIENCES, INC                                            | CUSIP: 000000000<br>LEI: N/A                  | Long             | DBT              | CORP              | US        |    235294 | PA      | $235294.00    | 0.03%             | 2026-01-01      | Fixed         | 8.00%                 | No            |                  3 | On Loan: No      |
| CARIS LIFE SCIENCES, INC         | CARIS LIFE SCIENCES, INC                                            | CUSIP: 000000000<br>LEI: N/A                  | Long             | EP               | CORP              | US        |    370370 | NS      | $2999997.00   | 0.35%             |  |  |  | Yes           |                  3 | On Loan: No      |
| Mettler-Toledo International Inc | Mettler-Toledo International Inc                                    | CUSIP: 592688105<br>LEI: 5493000BD5GJNUDIUG10 | Long             | EC               | CORP              | US        |      8731 | NS      | $10088845.12  | 1.17%             |  |  |  | No            |                  1 | On Loan: No      |
| Merck & Co Inc                   | Merck & Co Inc                                                      | CUSIP: 58933Y105<br>LEI: 4YV9Y5M8S0BRK1RP0397 | Long             | EC               | CORP              | US        |    126571 | NS      | $9725715.64   | 1.13%             |  |  |  | No            |                  1 | On Loan: No      |
| Coloplast A/S                    | Coloplast A/S                                                       | CUSIP: 000000000<br>LEI: 529900NN7SOJ5QG82X67 | Long             | EC               | CORP              | DK        |     81388 | NS      | $7912588.78   | 0.92%             |  |  |  | No            |                  2 | On Loan: No      |
| Eli Lilly & Co                   | Eli Lilly & Co                                                      | CUSIP: 532457108<br>LEI: FRDRIPF3EKNDJ2CQJL29 | Long             | EC               | CORP              | US        |    115906 | NS      | $85500379.02  | 9.92%             |  |  |  | No            |                  1 | On Loan: No      |
| Royalty Pharma PLC               | Royalty Pharma PLC                                                  | CUSIP: 000000000<br>LEI: 549300FGFN7VOK8BZR03 | Long             | EC               | CORP              | GB        |    180612 | NS      | $5938522.56   | 0.69%             |  |  |  | No            |                  1 | On Loan: No      |
| IDEXX Laboratories Inc           | IDEXX Laboratories Inc                                              | CUSIP: 45168D104<br>LEI: OGMTXK0LUU1HKV2P0J84 | Long             | EC               | CORP              | US        |     32781 | NS      | $16828454.16  | 1.95%             |  |  |  | No            |                  1 | On Loan: No      |
| Bristol-Myers Squibb Co          | Bristol-Myers Squibb Co                                             | CUSIP: 110122108<br>LEI: HLYYNH7UQUORYSJQCN42 | Long             | EC               | CORP              | US        |    497733 | NS      | $24030549.24  | 2.79%             |  |  |  | No            |                  1 | On Loan: No      |
| Gilead Sciences Inc              | Gilead Sciences Inc                                                 | CUSIP: 375558103<br>LEI: 549300WTZWR07K8MNV44 | Long             | EC               | CORP              | US        |    225867 | NS      | $24863439.36  | 2.89%             |  |  |  | No            |                  1 | On Loan: No      |

### Signature

**Date Signed:** 2025-06-27

**Name of Applicant:** Eaton Vance Growth Trust

**Signature:** James Kirchner

**Name of Signer:** James Kirchner

**Title:** Treasurer